Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1339-1344

  Chen, Guangdi ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell cycle; Cell proliferation; Cul1; Melanoma

Indexed keywords

CULLIN 1; PROTEIN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CULLIN PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 77957879187     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000786     Document Type: Article

References (38)

1. Diepgen TL and Mahler V: The epidemiology of skin cancer. Br J Dermatol 146 (Suppl. 61): 1-6, 2002.
2. Rigel DS, Friedman RJ and Kopf AW: The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 34: 839-847, 1996.
3. Rigel DS: The effect of sunscreen on melanoma risk. Dermatol Clin 20: 601-606, 2002.
4. Rigel DS: Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 58: S129-S132, 2008.
5. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001.
6. Houghton AN and Polsky D: Focus on melanoma. Cancer Cell 2: 275-278, 2002.
7. Trinh VA: Current management of metastatic melanoma. Am J Health Syst Pharm 65: S3-S8, 2008.
8. Paul S: Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. Bioessays 30: 1172-1184, 2008.
9. Hung MS, Mao JH, Xu Z, et al: Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 23: 572-574, 2010.
10. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21, 1994.
11. Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
12. Reinstein E and Ciechanover A: Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 145: 676-684, 2006. (Pubitemid 46768844)
13. Schrader EK, Harstad KG and Matouschek A: Targeting proteins for degradation. Nat Chem Biol 5: 815-822, 2009.
14. Vodermaier HC: APC/C and SCF: controlling each other and the cell cycle. Curr Biol 14: R787-R796, 2004.
15. Nakayama KI and Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381, 2006.
16. Dealy MJ, Nguyen KV, Lo J, et al: Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nat Genet 23: 245-248, 1999.
17. Ohh M, Kim WY, Moslehi JJ, et al: An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep 3: 177-182, 2002. (Pubitemid 34213497)
18. O'Hagan RC, Ohh M, David G, et al: Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 14: 2185-2191, 2000.
19. Chen G, Cheng Y, Martinka M and Li G: Cul1 expression is increased in early stages of human melanoma. Pigment Cell Melanoma Res (In press).
20. Skp2-mediated ubiquitin-proteasome system. Oncogene 29: 1498-1508, 2010.
21. Li G, Tang L, Zhou X, Tron V and Ho V: Chemotherapy-induced apoptosis in melanoma cells is p53-dependent. Melanoma Res 8: 17-23, 1998. (Pubitemid 28114297)
22. Reed SI: Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev Mol Cell Biol 4: 855-864, 2003.
23. Hochegger H, Takeda S and Hunt T: Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol 9: 910-916, 2008.
24. Lee MH and Yang HY: Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 22: 435-449, 2003.
25. Li W, Sanki A, Karim RZ, et al: The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38: 287-301, 2006. (Pubitemid 44266625)
26. Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1: 193-199, 1999. (Pubitemid 129500937)
27. Tsvetkov LM, Yeh KH, Lee SJ, Sun H and Zhang H: p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9: 661-664, 1999. (Pubitemid 129749921)
28. kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 31: 633-642, 2004.
29. KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 20: 501-508, 2005.
30. Kip1 and cyclin E degradation. Cell Cycle 5: 71-77, 2006.
31. Li B, Jia N, Kapur R and Chun KT: Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood 107: 4291-4299, 2006. (Pubitemid 43801353)
32. Kip1 for proteolysis involving the COP9 signalosome. Mol Cell Biol 26: 2531-2539, 2006.
33. Lim MS, Adamson A, Lin Z, et al: Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 100: 2950-2956, 2002.
34. Miranda-Carboni GA, Krum SA, Yee K, et al: A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 22: 3121-3134, 2008.
35. Li Y and McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29: 413-426, 2002. (Pubitemid 35178281)
36. Soengas MS and Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151, 2003.
37. Frescas D and Pagano M: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449, 2008. (Pubitemid 351744963)
38. Katagiri Y, Hozumi Y and Kondo S: Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 42: 215-224, 2006.